1. Home
  2. PCVX vs BIO Comparison

PCVX vs BIO Comparison

Compare PCVX & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vaxcyte Inc.

PCVX

Vaxcyte Inc.

HOLD

Current Price

$51.72

Market Cap

6.1B

Sector

Health Care

ML Signal

HOLD

Logo Bio-Rad Laboratories Inc.

BIO

Bio-Rad Laboratories Inc.

HOLD

Current Price

$294.21

Market Cap

8.7B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
PCVX
BIO
Founded
2013
1952
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Laboratory Analytical Instruments
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
6.1B
8.7B
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
PCVX
BIO
Price
$51.72
$294.21
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
4
Target Price
$105.00
$358.50
AVG Volume (30 Days)
1.1M
199.1K
Earning Date
02-24-2026
02-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,557,500,000.00
Revenue This Year
N/A
$1.62
Revenue Next Year
N/A
$2.26
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$27.66
$211.43
52 Week High
$93.77
$373.69

Technical Indicators

Market Signals
Indicator
PCVX
BIO
Relative Strength Index (RSI) 67.41 33.47
Support Level $44.85 $293.94
Resistance Level $56.04 $316.63
Average True Range (ATR) 2.65 8.98
MACD 0.76 -2.68
Stochastic Oscillator 74.09 0.72

Price Performance

Historical Comparison
PCVX
BIO

About PCVX Vaxcyte Inc.

Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.

About BIO Bio-Rad Laboratories Inc.

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

Share on Social Networks: